+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Middle East Gastric Cancer Diagnostics Market Size, Share & Trends Analysis Report by Product (Reagents & Consumables, Instruments), by Disease (Adenocarcinoma), by End Use (Diagnostic laboratories), by Country, and Segment Forecasts, 2025-2033- Product Image
Middle East Gastric Cancer Diagnostics Market Size, Share & Trends Analysis Report by Product (Reagents & Consumables, Instruments), by Disease (Adenocarcinoma), by End Use (Diagnostic laboratories), by Country, and Segment Forecasts, 2025-2033- Product Image
New

Middle East Gastric Cancer Diagnostics Market Size, Share & Trends Analysis Report by Product (Reagents & Consumables, Instruments), by Disease (Adenocarcinoma), by End Use (Diagnostic laboratories), by Country, and Segment Forecasts, 2025-2033

  • PDF Icon

    Report

  • 150 Pages
  • August 2025
  • Region: Middle East
  • Grand View Research
  • ID: 6168186
Description Jump to:
The Middle East gastric cancer diagnostics market size was estimated at USD 25.68 million in 2024 and is projected to reach USD 48.04 million by 2033, growing at a CAGR of 7.32% from 2025 to 2033. Growth in the gastric cancer diagnostics market in the Middle East is driven by rising disease burden and delayed detection rates, which are fueling demand for early screening and molecular testing. Strategic initiatives such as Mylab-AstraGene’s 2023 partnership in the UAE and Kuwait, Guardant Health-Hikma’s 2024 collaboration to expand liquid biopsy access, and the UAE’s 2025 approval of Biomerica’s Fortel H. pylori test are enhancing diagnostic capacity. In addition, biomarker adoption, including Claudin 18.2 testing at Burjeel Medical City in 2025, underscores increasing precision oncology integration

The gastric cancer diagnostics market in the Middle East is entering a period of accelerated growth, supported by significant regulatory approvals, commercial partnerships, and increasing healthcare investment. Although the overall incidence of gastric cancer in the region is lower compared to East Asia, late detection and limited survival rates are creating strong demand for early diagnostic solutions and precision oncology. Recent developments highlight how the market is evolving across screening, molecular diagnostics, and companion testing.

A major milestone came in March, 2023, when Mylab Discovery Solutions partnered with AstraGene in the UAE and Kuwait. This collaboration focuses on the co-development of automated molecular diagnostic solutions, including reagents, kits, and fully automated platforms. The initiative is expected to reduce reliance on imports, improve affordability, and build local capacity to meet the rising demand for oncology testing. Localized manufacturing also ensures compliance with regional regulatory frameworks and supports hospitals and laboratories with faster access to advanced molecular technologies.

Middle East Gastric Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth at regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. The analyst has segmented the Middle East gastric cancer diagnostics market report based on product, disease, end use, and country:

Product Outlook (Revenue, USD Million, 2021-2033)

  • Reagents & Consumables
  • Instruments

Disease Outlook (Revenue, USD Million, 2021-2033)

  • Adenocarcinoma
  • Gastric lymphoma
  • Others

End-Use Outlook (Revenue, USD Million, 2021-2033)

  • Hospitals
  • Diagnostic Laboratories
  • Diagnostic Imaging

Country Outlook (Revenue, USD Million, 2021-2033)

  • Middle East
  • South Africa
  • UAE
  • Kuwait
  • Oman
  • Qatar

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the industry across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segmental and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Disease
1.2.3. End Use
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline.
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Disease outlook
2.2.3. End Use outlook
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. ME Gastric Cancer Diagnostics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. ME Gastric Cancer Diagnostics Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
Chapter 4. ME Gastric Cancer Diagnostics Market: Product Estimates & Trend Analysis
4.1. Product Market Share, 2024 & 2033
4.2. Segment Dashboard
4.3. ME Gastric Cancer Diagnostics Market: Product Movement Analysis
4.4. ME Gastric Cancer Diagnostics Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
4.5. ME Gastric Cancer Diagnostics Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
4.6. Reagents & consumables
4.6.1. Reagents & consumables Market estimates and forecasts 2021 to 2033 (USD Million)
4.7. Instruments
4.7.1. Instruments Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 5. ME Gastric Cancer Diagnostics Market: Disease Estimates & Trend Analysis
5.1. Disease Market Share, 2024 & 2033
5.2. Segment Dashboard
5.3. ME Gastric Cancer Diagnostics Market by Disease Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
5.5. Adenocarcinoma
5.5.1. Adenocarcinoma Market estimates and forecasts 2021 to 2033 (USD Million)
5.6. Gastric lymphoma
5.6.1. Gastric lymphoma Market estimates and forecasts 2021 to 2033 (USD Million)
5.7. Others
5.7.1. Others Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 6. ME Gastric Cancer Diagnostics Market: End Use Estimates & Trend Analysis
6.1. End Use Market Share, 2024 & 2033
6.2. Segment Dashboard
6.3. ME Gastric Cancer Diagnostics Market by End Use Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
6.5. Hospitals
6.5.1. Hospitals Market estimates and forecasts 2021 to 2033 (USD Million)
6.6. Diagnostic Laboratories
6.6.1. Diagnostic Laboratories Market estimates and forecasts 2021 to 2033 (USD Million)
6.7. Diagnostic Imaging
6.7.1. Diagnostic Imaging Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 7. ME Gastric Cancer Diagnostics Market: Country Estimates & Trend Analysis
7.1. Country Market Share Analysis, 2024 & 2033
7.2. Country Market Dashboard
7.3. Country Market Snapshot
7.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
7.5. ME
7.5.1. Saudi Arabia
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/Reimbursement
7.5.1.3. Competitive scenario
7.5.1.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
7.5.2. UAE
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/Reimbursement
7.5.2.3. Competitive scenario
7.5.2.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
7.5.3. Kuwait
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework
7.5.3.3. Competitive scenario
7.5.3.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
7.5.4. Oman
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/Reimbursement
7.5.4.3. Competitive scenario
7.5.4.4. Oman market estimates and forecasts 2021 to 2033 (USD Million)
7.5.5. Qatar
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/Reimbursement
7.5.5.3. Competitive scenario
7.5.5.4. Qatar market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, by Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2024
8.3.4. MiRXES Pte Ltd.
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Agilent Technologies Inc
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Endofotonics Pte Ltd
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Bio-Rad Laboratories, Inc
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Hipro Biotechnology Co.,Ltd
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Exact Sciences Corporation
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. QIAGEN
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Fulgent Genetics.
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
8.3.12. F. Hoffmann-La Roche Ltd
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Product benchmarking
8.3.12.4. Strategic initiatives
8.3.13. Abbott
8.3.13.1. Company overview
8.3.13.2. Financial performance
8.3.13.3. Product benchmarking
8.3.13.4. Strategic initiatives
List of Tables
Table 1 List of abbreviations
Table 2 ME Gastric Cancer Diagnostics market, by product, 2021-2033 (USD Million)
Table 3 ME Gastric Cancer Diagnostics market, by disease, 2021-2033 (USD Million)
Table 4 ME Gastric Cancer Diagnostics market, by end use, 2021-2033 (USD Million)
Table 5 Saudi Arabia Gastric Cancer Diagnostics market, by product, 2021-2033 (USD Million)
Table 6 Saudi Arabia Gastric Cancer Diagnostics market, by disease, 2021-2033 (USD Million)
Table 7 Saudi Arabia Gastric Cancer Diagnostics market, by end use, 2021-2033 (USD Million)
Table 8 UAE Gastric Cancer Diagnostics market, by product, 2021-2033 (USD Million)
Table 9 UAE Gastric Cancer Diagnostics market, by disease, 2021-2033 (USD Million)
Table 10 UAE Gastric Cancer Diagnostics market, by end use, 2021-2033 (USD Million)
Table 11 Kuwait Gastric Cancer Diagnostics market, by product, 2021-2033 (USD Million)
Table 12 Kuwait Gastric Cancer Diagnostics market, by disease, 2021-2033 (USD Million)
Table 13 Kuwait Gastric Cancer Diagnostics market, by end use, 2021-2033 (USD Million)
Table 14 Qatar Gastric Cancer Diagnostics market, by product, 2021-2033 (USD Million)
Table 15 Qatar Gastric Cancer Diagnostics market, by disease, 2021-2033 (USD Million)
Table 16 Qatar Gastric Cancer Diagnostics market, by end use, 2021-2033 (USD Million)
Table 17 Oman Gastric Cancer Diagnostics market, by product, 2021-2033 (USD Million)
Table 18 Oman Gastric Cancer Diagnostics market, by disease, 2021-2033 (USD Million)
Table 19 Oman Gastric Cancer Diagnostics market, by end use, 2021-2033 (USD Million)
List of Figures
Figure 1 Market research process
Figure 2 Data triangulation techniques
Figure 3 Primary research pattern
Figure 4 Primary interviews in North America
Figure 5 Primary interviews in Europe
Figure 6 Primary interviews in APAC
Figure 7 Primary interviews in Latin America
Figure 8 Primary interviews in MEA
Figure 9 Market research approaches
Figure 10 Value-chain-based sizing & forecasting
Figure 11 QFD modeling for market share assessment
Figure 12 Market formulation & validation
Figure 13 Gastric Cancer Diagnostics market: market outlook
Figure 14 Gastric Cancer Diagnostics competitive insights
Figure 15 Parent market outlook
Figure 16 Related/ancillary market outlook
Figure 17 Penetration and growth prospect mapping
Figure 18 Industry value chain analysis
Figure 19 Gastric Cancer Diagnostics market driver impact
Figure 20 Gastric Cancer Diagnostics market restraint impact
Figure 21 Gastric Cancer Diagnostics market strategic initiatives analysis
Figure 22 Gastric Cancer Diagnostics market: Product movement analysis
Figure 23 Gastric Cancer Diagnostics market: Product outlook and key takeaways
Figure 24 Reagents & consumables market estimates and forecasts, 2021-2033
Figure 25 Instruments market estimates and forecasts,2021-2033
Figure 26 ME Gastric Cancer Diagnostics Market: Disease movement analysis
Figure 27 Gastric Cancer Diagnostics market: Disease outlook and key takeaways
Figure 28 Adenocarcinoma market estimates and forecasts, 2021-2033
Figure 29 Gastric lymphoma market estimates and forecasts, 2021-2033
Figure 30 Others market estimates and forecasts, 2021-2033
Figure 31 ME Gastric Cancer Diagnostics Market: End Use movement analysis
Figure 32 Gastric Cancer Diagnostics market: End Use outlook and key takeaways
Figure 33 Hospitals market estimates and forecasts, 2021-2033
Figure 34 Diagnostic Laboratories market estimates and forecasts, 2021-2033
Figure 35 Diagnostic Imaging market estimates and forecasts, 2021-2033
Figure 36 Gastric Cancer Diagnostics market: Country movement analysis
Figure 37 Gastric Cancer Diagnostics market: Country outlook and key takeaways
Figure 38 Gastric Cancer Diagnostics market share and leading players
Figure 39 Middle East
Figure 40 Middle East market estimates and forecasts, 2021-2033
Figure 41 Saudi Arabia
Figure 42 Saudi Arabia market estimates and forecasts, 2021-2033
Figure 43 UAE
Figure 44 UAE market estimates and forecasts, 2021-2033
Figure 45 Kuwait
Figure 46 Kuwait market estimates and forecasts, 2021-2033
Figure 47 Oman
Figure 48 Oman market estimates and forecasts, 2021-2033
Figure 49 Qatar
Figure 50 Qatar market estimates and forecasts, 2021-2033
Figure 51 Market share of key market players- Gastric Cancer Diagnostics market

Companies Mentioned

The major companies profiled in this Middle East Gastric Cancer Diagnostics market report include:
  • MiRXES Pte Ltd
  • Agilent Technologies Inc
  • Endofotonics Pte Ltd
  • Bio-Rad Laboratories, Inc
  • Hipro Biotechnology Co., Ltd
  • F. Hoffmann-La Roche Ltd.
  • Exact Sciences Corporation
  • QIAGEN
  • Fulgent Genetics
  • Abbott

Table Information

Report AttributeDetails
No. of Pages150
PublishedAugust 2025
Forecast Period2024 - 2033
Estimated Market Value ( USD ) in 2024 $ 25.68 Million
Forecasted Market Value ( USD ) by 2033 $ 48.04 Million
Compound Annual Growth Rate7.3%
Regions CoveredMiddle East
No. of Companies Mentioned11

Related Topics

Related Reports

Gastric Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product (Reagents & Consumables, Instruments), By Disease Type (Adenocarcinoma, Gastric lymphoma), By End Use, By Region And Segment Forecasts, 2025 - 2033 - Product Image

Gastric Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product (Reagents & Consumables, Instruments), By Disease Type (Adenocarcinoma, Gastric lymphoma), By End Use, By Region And Segment Forecasts, 2025 - 2033

  • Report
  • 150 Pages
  • Global
From
U.S. Gastric Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product (Reagents & Consumables, Instruments), By Disease Type (Adenocarcinoma, Gastric Lymphoma), By End-use (Diagnostic Laboratories), And Segment Forecasts, 2025 - 2033 - Product Image

U.S. Gastric Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product (Reagents & Consumables, Instruments), By Disease Type (Adenocarcinoma, Gastric Lymphoma), By End-use (Diagnostic Laboratories), And Segment Forecasts, 2025 - 2033

  • Report
  • 150 Pages
  • United States
From
Middle East Hereditary Cancer Testing Market Size, Share & Trends Analysis Report by Cancer, by Technology (Cytogenetic, Biochemical, Molecular Testing), by Test Type (Predictive Testing, Diagnostic Testing), by End-use, by Country, and Segment Forecasts, 2025-2033 - Product Image

Middle East Hereditary Cancer Testing Market Size, Share & Trends Analysis Report by Cancer, by Technology (Cytogenetic, Biochemical, Molecular Testing), by Test Type (Predictive Testing, Diagnostic Testing), by End-use, by Country, and Segment Forecasts, 2025-2033

  • Report
  • 320 Pages
  • Middle East
From
Hereditary Cancer Testing Market Size, Share & Trends Analysis Report by Cancer, by Technology (Cytogenetic, Biochemical, Molecular Testing), by Test Type (Predictive Testing, Diagnostic Testing), by End Use, by Region, and Segment Forecasts, 2025-2033 - Product Image

Hereditary Cancer Testing Market Size, Share & Trends Analysis Report by Cancer, by Technology (Cytogenetic, Biochemical, Molecular Testing), by Test Type (Predictive Testing, Diagnostic Testing), by End Use, by Region, and Segment Forecasts, 2025-2033

  • Report
  • 150 Pages
  • Global
From
U.S. Hereditary Cancer Testing Market Size, Share & Trends Analysis Report by Cancer, by Technology (Cytogenetic, Biochemical, Molecular Testing), by Test Type (Predictive Testing, Diagnostic Testing), by End-use (Hospitals, Clinics), and Segment Forecasts, 2025 to 2033 - Product Image

U.S. Hereditary Cancer Testing Market Size, Share & Trends Analysis Report by Cancer, by Technology (Cytogenetic, Biochemical, Molecular Testing), by Test Type (Predictive Testing, Diagnostic Testing), by End-use (Hospitals, Clinics), and Segment Forecasts, 2025 to 2033

  • Report
  • 150 Pages
  • United States
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.